American Association for Cancer Research
crc-23-0384_fig5.png (284.72 kB)

FIGURE 5 from Identification of Enhanced Vaccine Mimotopes for the p15E Murine Cancer Antigen

Download (284.72 kB)
posted on 2024-04-02, 14:20 authored by Shiqi Zhou, Yiting Song, Yuan Luo, Breandan Quinn, Yang Jiao, Mark D. Long, Scott I. Abrams, Jonathan F. Lovell

p15E-3C mimotope-induced inhibition of MC38 tumor growth is CD8+ T-cell dependent. Mice received 2 µg p15E-3C liposomal vaccine on days 0 and 7 before challenge with 1 × 106 MC-38 cells on day 14 (n = 6). A, Schedule of injections and tumor inoculation. Mice received 400 µg CD8 MAb or CD4 MAb on day 12 and day 13 as indicated; 200 µg CD8 mAb or CD4 mAb on day 18 and day 22 as indicated. B, Average tumor volume of indicated groups. C, Percentage of mice with tumor length shorter than 10 mm. D, Tumor volumes of individual mice from indicated groups. Datapoints represent mean values of 6 mice from the same group for B. Error bars show mean − SD.


HHS | National Institutes of Health (NIH)



Mimotopes of short CD8+ T-cell epitopes generally comprise one or more mutated residues, and can increase the immunogenicity and function of peptide cancer vaccines. We recently developed a two-step approach to generate enhanced mimotopes using positional peptide microlibraries and herein applied this strategy to the broadly used H-2Kb–restricted murine leukemia p15E tumor rejection epitope. The wild-type p15E epitope (sequence: KSPWFTTL) was poorly immunogenic in mice, even when combined with a potent peptide nanoparticle vaccine system and did not delay p15E-expressing MC38 tumor growth. Following positional microlibrary functional screening of over 150 mimotope candidates, two were identified, both with mutations at residue 3 (p15E-P3C; “3C,” and p15E-P3M; “3M”) that better induced p15E-specific CD8+ T cells and led to tumor rejection. Although 3M was more immunogenic, 3C effectively delayed tumor growth in a therapeutic setting relative to the wild-type p15E. As 3C had less H-2Kb affinity relative to both p15E and 3M, 15 additional mimotope candidates (all that incorporated the 3C mutation) were assessed that maintained or improved predicted MHC-I affinity. Valine substitution at position 2 (3C2V, sequence: KVCWFTTL) led to improved p15E-specific immunogenicity, tumor rejection, and subsequent long-term antitumor immunity. 3C, 3M, and 3C2V mimotopes were more effective than p15E in controlling MC38 and B16-F10 tumors. T-cell receptor (TCR) sequencing revealed unique TCR transcripts for mimotopes, but there were no major differences in clonality. These results provide new p15E mimotopes for further vaccine use and illustrate considerations for MHC-I affinity, immunogenicity, and functional efficacy in mimotope design. The MHC-I–restricted p15E tumor rejection epitope is expressed in multiple murine cancer lines and is used as a marker of antitumor cellular immunity, but has seen limited success as a vaccine immunogen. An in vivo screening approach based on a positional peptide microlibraries is used to identify enhanced p15E mimotopes bearing amino acid mutations that induce significantly improved functional immunogenicity relative to vaccination with the wild-type epitope.

Usage metrics

    Cancer Research Communications



    Ref. manager